Health Canada’s Updated NHP Framework: What Changed and How to Protect Your Business
Health Canada's updated NHP regulations enforce stricter labeling, GMP, site licence, and post-market rules, raising compliance risks and costs; partnering…
Best Practices for Building an Effective Medical Device Submission Strategy for the US FDA and Health Canada
Develop a clear FDA and Health Canada submission strategy by understanding 510(k), De Novo, PMA, and licensing pathways, ensuring robust…
From Silos to Synergy: A Practical Blueprint to Integrate Your QMS for Global Compliance
This blueprint guides integrating QMS for global compliance, emphasizing process harmonization, eQMS validation, regulatory navigation (FDA, EU MDR, GMP), robust…
Post-Approval Compliance and Risk Management: What Every RA/QA Leader Must Control in the US and Canada
Post-approval compliance in the US and Canada demands robust risk management, pharmacovigilance, complaint handling, and QMS aligned with FDA and…
Continuous Regulatory Intelligence: Your Edge in a Regulated Market
Continuous regulatory intelligence enables proactive tracking of FDA and Health Canada updates, reducing risk, accelerating approvals, and sustaining competitive advantage.…
Medical Device Licensing in Canada and the US: A Step-by-Step Guide to MDEL/MDL, FDA 510(k), De Novo, and PMA
This guide details Canadian (MDEL/MDL) and US (FDA 510(k), De Novo, PMA) medical device licensing steps: classification, QMS, evidence, submissions,…
How to Ensure Cosmetic Ingredient Compliance With FDA MoCRA and Health Canada
This guide details FDA MoCRA and Health Canada cosmetic compliance, covering ingredient screening, labeling, safety, cross-border rules, and highlights Arora…
Navigating International Cosmetic Compliance: Common Challenges and Practical Solutions
This guide highlights challenges in international cosmetic compliance—US MoCRA, EU 1223/2009, Health Canada—and offers practical solutions like INCI labeling, claims…
